Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRAF Mutated Melanoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT02039947
What this trial is testing

Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain

Who this might be right for
Melanoma and Brain Metastases
Novartis Pharmaceuticals 127
Testing effectiveness (Phase 2)Active Not RecruitingNCT04722575
What this trial is testing

Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma

Who this might be right for
Melanoma
Fondazione Melanoma Onlus 95
Large-scale testing (Phase 3)Active Not RecruitingNCT04657991
What this trial is testing

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

Who this might be right for
Melanoma
Pfizer 257
Not applicableStudy completedNCT05806268
What this trial is testing

Patient Characteristics, Associated Factors, and Clinical Outcomes of Prescribing Encorafenib and Binimetenib Versus Dabrafenib and Trametinib Among BRAF v600 Mutated Metastatic Melanoma Patients

Who this might be right for
BRAF v600 Mutated Metastatic Melanoma
Novartis Pharmaceuticals 214
Not applicableStudy completedNCT07256184
What this trial is testing

Prognostic and Treatment-Response Factors in Metastatic Melanoma: Multi-Center Analysis

Who this might be right for
Metastatic Malignant Melanoma
Ankara Etlik City Hospital 232
Not applicableAvailableNCT04566393
What this trial is testing

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

Who this might be right for
Pancreatic CancerSmall Bowel CancerColorectal Cancer+18 more
xCures
Early research (Phase 1)Ended earlyNCT01876641
What this trial is testing

Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib

Who this might be right for
Metastatic MelanomaMelanomaBRAF-mutated Metastatic Melanoma+1 more
Mohammed M Milhem 18
Early research (Phase 1)Study completedNCT01436656
What this trial is testing

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

Who this might be right for
Melanoma and Metastatic Colorectal Cancer
Pfizer 107
Testing effectiveness (Phase 2)UnknownNCT02036086
What this trial is testing

Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases

Who this might be right for
Melanoma
Sunnybrook Health Sciences Centre 24
Testing effectiveness (Phase 2)Active Not RecruitingNCT04557956
What this trial is testing

Testing the Addition of the Anti-cancer Drug, Tazemetostat, to (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment

Who this might be right for
Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Melanoma
National Cancer Institute (NCI) 16
Not applicableNo Longer AvailableNCT04544202
What this trial is testing

Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection

Who this might be right for
MelanomaAdjuvant
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Study completedNCT01266967
What this trial is testing

GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain

Who this might be right for
Melanoma and Brain Metastases
GlaxoSmithKline 172
Not applicableStudy completedNCT05260684
What this trial is testing

Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US

Who this might be right for
Melanoma
Pfizer 716
Not applicableStudy completedNCT01990248
What this trial is testing

An Observational Safety Study in Zelboraf (Vemurafenib)-Treated Patients With BRAF-V600 Mutation-Positive Unresectable or Metastatic Melanoma (ZeSS)

Who this might be right for
Malignant Melanoma
Hoffmann-La Roche 339
Testing effectiveness (Phase 2)WithdrawnNCT03972046
What this trial is testing

Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma

Who this might be right for
Melanoma (Skin)Melanoma Stage IIIb-IVM1aMetastasis Skin+2 more
TriHealth Inc.
Early research (Phase 1)Study completedNCT01767454
What this trial is testing

Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma

Who this might be right for
Solid Tumours
GlaxoSmithKline 38
Testing effectiveness (Phase 2)Ended earlyNCT04655157
What this trial is testing

Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma

Who this might be right for
Melanoma
Jason J. Luke, MD 2
Post-approval studies (Phase 4)Looking for participantsNCT03340506
What this trial is testing

Dabrafenib and/or Trametinib Rollover Study

Who this might be right for
MelanomaNon Small Cell Lung CancerSolid Tumor+2 more
Novartis Pharmaceuticals 100
Early research (Phase 1)UnknownNCT05103891
What this trial is testing

Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations

Who this might be right for
MelanomaBRAF V600 MutationUnresectable Melanoma+1 more
Pierre Fabre Medicament 14
Testing effectiveness (Phase 2)Ended earlyNCT03430947
What this trial is testing

Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases

Who this might be right for
Malignant Melanoma Stage IVBRAF V600 MutationBrain Metastases
Technische Universität Dresden 20
Next Page